Marc D. Natter

Marc D. Natter

Auto-generated profile, based on publicly available information

Marc D. Natter

Computational Health Informatics Program, Boston Children’s Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
SASteven Abman
Steven Abman
MMMary P. Mullen
Mary P. Mullen
LSLynn A. Sleeper
Lynn A. Sleeper
EAEric D. Austin
Eric D. Austin
BRBerman Rosenzweig
Berman Rosenzweig
KMKenneth D. Mandl
Kenneth D. Mandl
To characterise the clinical features of diseases associated with paediatric pulmonary hypertension, including natural history, evaluation and therapeutic interventions, longitudinal data from 1500 children from major PH programmes were analysedhttps://bit.ly/3ff3zjV

6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MOMei Sing Ong
Mei Sing Ong
JKJeff Klann
Jeff Klann
KLKueiyu Joshua Lin
Kueiyu Joshua Lin
BMBradley A. Maron
Bradley A. Maron
SMShawn N. Murphy
Shawn N. Murphy
KMKenneth D. Mandl
Kenneth D. Mandl
Background: Real‐world healthcare data are an important resource for epidemiologic research. However, accurate identification of patient cohorts—a crucial first step underpinning the validity of research results—remains a challenge. We developed and evaluated claims‐based case ascertainment algorithms for pulmonary hypertension (PH), comparing conventional decision rules with state‐of‐the‐art machine‐learning approaches. Methods and Results: We analyzed an electronic health record‐Medicare linked database from two large academic tertiary care hospitals (years 2007–2013). Electronic health record charts were reviewed to form a gold standard cohort of patients with (n=386) and without PH (n=164). Using health encounter data captured in Medicare claims (including patients’ demographics, diagnoses, medications, and procedures), we developed and compared 2 approaches for identifying patients with PH: decision rules and machine‐learning algorithms using penalized lasso regression, random forest, and gradient boosting machine. The most optimal rule‐based algorithm—having ≥3 PH‐related healthcare encounters and having undergone right heart catheterization—attained an area under the receiver operating characteristic curve of 0.64 (sensitivity, 0.75; specificity, 0.48). All 3 machine‐learning algorithms outperformed the most optimal rule‐based algorithm ( P <0.001). A model derived from the random forest algorithm achieved an area under the receiver operating characteristic curve of 0.88 (sensitivity, 0.87; specificity, 0.70), and gradient boosting machine achieved comparable results (area under the receiver operating characteristic curve, 0.85; sensitivity, 0.87; specificity, 0.70). Penalized lasso regression achieved an area under the receiver operating characteristic curve of 0.73 (sensitivity, 0.70; specificity, 0.68). Conclusions: Research‐grade case identification algorithms for PH can be derived and rigorously validated using machine‐learning algorithms. Simple decision rules commonly applied in published literature performed poorly; more complex rule‐based algorithms may potentially address the limitation of this approach. PH research using claims data would be considerably strengthened through the use of validated algorithms for cohort ascertainment.

25 March 2022 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
LKLianne Kearsley-Fleet
Lianne Kearsley-Fleet
MCMin-Lee Chang
Min-Lee Chang
SLSaskia Lawson-Tovey
Saskia Lawson-Tovey
RCRuth Costello
Ruth Costello
ŠFŠárka Fingerhutová
Šárka Fingerhutová
KHKimme L Hyrich
Kimme L Hyrich
Objectives Some adults with rheumatic and musculoskeletal diseases (RMDs) are at increased risk of COVID-19-related death. Excluding post-COVID-19 multisystem inflammatory syndrome of children, children and young people (CYP) are overall less prone to severe COVID-19 and most experience a mild or asymptomatic course. However, it is unknown if CYP with RMDs are more likely to have more severe COVID-19. This analysis aims to describe outcomes among CYP with underlying RMDs with COVID-19. Methods Using the European Alliance of Associations for Rheumatology COVID-19 Registry, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, and the CARRA-sponsored COVID-19 Global Paediatric Rheumatology Database, we obtained data on CYP with RMDs who reported SARS-CoV-2 infection (presumptive or confirmed). Patient characteristics and illness severity were described, and factors associated with COVID-19 hospitalisation were investigated. Results 607 CYP with RMDs <19 years old from 25 different countries with SARS-CoV-2 infection were included, the majority with juvenile idiopathic arthritis (JIA; n=378; 62%). Forty-three (7%) patients were hospitalised; three of these patients died. Compared with JIA, diagnosis of systemic lupus erythematosus, mixed connective tissue disease, vasculitis, or other RMD (OR 4.3; 95% CI 1.7 to 11) or autoinflammatory syndrome (OR 3.0; 95% CI 1.1 to 8.6) was associated with hospitalisation, as was obesity (OR 4.0; 95% CI 1.3 to 12). Conclusions This is the most significant investigation to date of COVID-19 in CYP with RMDs. It is important to note that the majority of CYP were not hospitalised, although those with severe systemic RMDs and obesity were more likely to be hospitalised.

1 February 2022 in Rheumatic Disease Clinics of North America
Verified
Journal Article
Closed access
ATAlysha J. Taxter
Alysha J. Taxter
MNMarc D. Natter
Marc D. Natter